Modera Wealth Management LLC lessened its stake in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 6.4% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,208 shares of the medical research company’s stock after selling 7,796 shares during the quarter. Modera Wealth Management LLC’s holdings in Amgen were worth $36,477,000 as of its most recent SEC filing.
A number of other large investors have also recently made changes to their positions in the stock. Hershey Financial Advisers LLC purchased a new stake in Amgen during the 2nd quarter valued at $30,000. nVerses Capital LLC purchased a new stake in Amgen during the second quarter valued at $31,000. Bbjs Financial Advisors LLC bought a new stake in shares of Amgen during the 2nd quarter valued at about $33,000. Matrix Trust Co bought a new position in shares of Amgen in the 3rd quarter worth approximately $36,000. Finally, FSA Wealth Management LLC grew its position in Amgen by 182.0% during the first quarter. FSA Wealth Management LLC now owns 141 shares of the medical research company’s stock valued at $40,000 after buying an additional 91 shares during the period. 76.50% of the stock is currently owned by institutional investors.
Amgen Price Performance
AMGN stock opened at $316.98 on Friday. The company has a fifty day simple moving average of $325.49 and a two-hundred day simple moving average of $313.77. Amgen Inc. has a 52 week low of $249.70 and a 52 week high of $346.85. The company has a quick ratio of 0.89, a current ratio of 1.26 and a debt-to-equity ratio of 9.64. The firm has a market capitalization of $170.04 billion, a P/E ratio of 45.28, a price-to-earnings-growth ratio of 2.86 and a beta of 0.61.
Amgen Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Monday, December 9th. Investors of record on Monday, November 18th will be given a $2.25 dividend. This represents a $9.00 dividend on an annualized basis and a yield of 2.84%. Amgen’s dividend payout ratio is presently 128.57%.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently issued reports on AMGN shares. Cantor Fitzgerald reissued an “overweight” rating and set a $405.00 price objective on shares of Amgen in a research report on Tuesday, October 22nd. Truist Financial cut Amgen from a “buy” rating to a “hold” rating and upped their price target for the stock from $320.00 to $333.00 in a research report on Monday, October 14th. Wells Fargo & Company cut Amgen from an “overweight” rating to an “equal weight” rating and lifted their price objective for the company from $320.00 to $335.00 in a research report on Wednesday, August 7th. Dbs Bank raised shares of Amgen to a “strong-buy” rating in a report on Monday, September 16th. Finally, Royal Bank of Canada restated an “outperform” rating and set a $362.00 target price on shares of Amgen in a research note on Thursday, September 26th. One analyst has rated the stock with a sell rating, eleven have assigned a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $332.55.
Check Out Our Latest Stock Report on Amgen
Amgen Company Profile
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Recommended Stories
- Five stocks we like better than Amgen
- How to Effectively Use the MarketBeat Ratings Screener
- Real Estate Sector Outperforms: 3 Stocks to Gain Exposure
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- 3 Fintech Stocks With Good 2021 Prospects
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN – Free Report).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.